we also consider trends related to certain key financial data , including gross profit margin , selling and administrative expense , investment in research and development , return on invested capital , and cash flows . on october 5 , 2014 , we announced a definitive agreement under which bd will acquire 100 % of carefusion corporation ( carefusion ) for $ 58.00 per share in cash and stock , or a total of approximately $ 12.2 billion , to create a global leader in medication management and patient safety solutions . the transaction is expected to close in the first half of calendar year 2015. under the terms of the transaction , carefusion stockholders will receive $ 49.00 in cash , without interest , and 0.0777 of a share of bd for each share of carefusion . using bd 's closing price as of october 3 , 2014 of $ 115.84 would result in a total cost of $ 58.00 per carefusion share . the value of the consideration transferred for accounting purposes will ultimately be based on the closing share price of bd 's stock on the last trading day prior to the closing date of the transaction , and could materially change . carefusion will operate as part of our medical segment . additional discussion regarding this agreement is provided in note 17 to the consolidated financial statements contained in item 8. financial statements and supplementary data . summary of financial results worldwide revenues in 2014 of $ 8.446 billion increased 4.9 % from the prior year , compared with an increase of 4.5 % in 2013. the components of the total worldwide revenue growth in 2014 and 2013 were as follows : replace_table_token_6_th significant drivers of worldwide revenue growth in 2014 included new product sales and sales in emerging markets . strong medical segment revenue growth in 2014 was driven by emerging market and international safety sales , as well as by sales of insulin pen needles . diagnostics revenue growth in 2014 reflected strong sales of safety-engineered products , as well as solid sales of automated diagnostic platforms and automated microbiology systems . diagnostics revenue growth continues to be unfavorably impacted by continued weaker sales of our women 's health and cancer platform . our biosciences segment 's revenue growth in 2014 was driven primarily by double-digit growth of sales in emerging markets and strong clinical reagent sales in all regions . 22 revenues in the united states of $ 3.417 billion in 2014 increased 1.9 % from 2013. international revenues in 2014 grew 7.0 % to $ 5.029 billion , which reflected an estimated unfavorable foreign exchange translation impact of 0.6 % . u.s. revenue growth in 2014 reflected strong medical and biosciences revenue growth , which was partially offset by the ongoing weaker demand in the diagnostics segment 's women 's health and cancer platform . sales of safety-engineered products in the united states were $ 1.2 billion . international revenues for 2014 reflected growth from all segments , including growth attributable to emerging markets , as well as strong sales of safety-engineered products . international safety-engineered products revenues of $ 1.016 billion grew 10.8 % , including an estimated unfavorable impact of foreign currency translation of 1.5 % , reflecting strong performance in western europe and emerging markets . we continue to invest in research and development , geographic expansion , and new product promotions to drive further revenue and profit growth . our ability to sustain our long-term growth will depend on a number of factors , including our ability to expand our core business ( including geographical expansion ) , develop innovative new products , and continue to improve operating efficiency and organizational effectiveness . while the economic environment for the healthcare industry has stabilized , pricing pressures continue for some of our products . healthcare utilization has continued to stabilize in the united states ; however , any destabilization could adversely impact our u.s. businesses . additionally , macroeconomic challenges in europe continue to constrain healthcare utilization , although we currently view the environment as stable . in emerging markets , the company 's growth is dependent on government funding for healthcare systems . in addition to the economic conditions in the united states and elsewhere , numerous other factors can affect our ability to achieve our goals including , without limitation , increased competition and healthcare reform initiatives . for example , the u.s. patient protection affordable care act contains the medical device excise tax that imposed a 2.3 % tax on certain u.s. sales of medical devices . this tax became effective at the beginning of bd 's second quarter of fiscal year 2013. as a result , this tax incrementally increased selling and administrative expense by $ 14 million in 2014 compared with 2013 , and by $ 40 million in 2013 compared with 2012. our financial position remains strong , with cash flows from operating activities totaling $ 1.75 billion in 2014. at september 30 , 2014 , we had $ 2.74 billion in cash and equivalents and short-term investments . also , we continued to return value to our shareholders in the form of share repurchases and dividends . during 2014 , we repurchased $ 400 million of our common stock and paid cash dividends of $ 421 million . no share repurchases are planned in 2015 , as our share repurchase program has been suspended in connection with the announced agreement to acquire carefusion . each reporting period , we face currency exposure that arises from translating the results of our worldwide operations to the u.s. dollar at exchange rates that fluctuate from the beginning of such period . we evaluate our results of operations on both a reported and a foreign currency-neutral basis , which excludes the impact of fluctuations in foreign currency exchange rates . story_separator_special_tag research and development expense in 2014 additionally reflected ongoing investment in new products and platforms within the medical segment . expenses in 2013 reflected increased investment in new products and platforms in all three segments . net interest expense replace_table_token_13_th the decrease in interest expense in 2014 compared with 2013 primarily reflected lower levels of long-term fixed-rate debt and a reduction of interest payments through fixed-to-floating interest rate swap agreements . for further discussion regarding these swap arrangements , refer to note 12 to the consolidated financial statements contained in item 8. financial statements and supplementary data . the increase in interest expense in 2013 compared with 2012 primarily reflected higher average levels of long-term fixed-rate debt . the increase in interest income in 2014 compared with 2013 reflected higher interest rates on investments outside the united states , partially offset by the impact of lower investment gains on assets related to our deferred compensation plan . the decrease in interest income in 2013 compared with 2012 reflected the impact of lower interest rates on investments outside the u.s. and lower investment gains on assets related to our deferred compensation plan . the offsetting movements in the deferred compensation plan liability were recorded in selling and administrative expense . income taxes the effective tax rate in 2014 was 22.1 % as compared with the 2013 rate of 20.2 % . the effective income tax rate in 2013 would have been higher by 430 basis points excluding the impact on bd 's income mix of the 28 previously discussed litigation matters and pension settlement . the effective income tax rate in 2014 reflected our decision to change our position of permanent reinvestment , with respect to the unremitted earnings of brazil and certain other latin american jurisdictions , the impact of which was more than offset by the benefits resulting from discrete one-time items and geographic mix . the effective income tax rate in 2013 also reflected the favorable impact from various tax settlements in multiple jurisdictions and the reinstatement of the u.s. research and development tax credit , partially offset by a lower benefit on foreign earnings . the effective income tax rate of 24.6 % in 2012 , which was reduced by 20 basis points due to the 2012 pension settlement charge , reflected the favorable impact of various tax settlements in multiple jurisdictions . income and diluted earnings per share from continuing operations income from continuing operations and diluted earnings per share from continuing operations in 2014 were $ 1.185 billion and $ 5.99 , respectively . the previously discussed specified items recorded in 2014 decreased diluted earnings per share from continuing operations by $ 0.25. in addition , the medical device excise tax was in effect for an additional quarter in 2014 compared with 2013 , the impact of which was $ 0.05. the current year 's earnings additionally reflected an estimated $ 0.22 unfavorable impact compared with 2013 from foreign currency translation . income from continuing operations and diluted earnings per share from continuing operations in 2013 were $ 929 million and $ 4.67 , respectively . the previously discussed specified items recorded in 2013 decreased diluted earnings per share from continuing operations in 2013 by $ 1.15. earnings in 2013 also reflected an estimated net unfavorable impact compared with 2012 of foreign currency fluctuations of $ 0.06 per share and an unfavorable impact from the medical device excise tax of $ 0.13 per share . income from continuing operations and diluted earnings per share from continuing operations in 2012 were $ 1.1 billion and $ 5.30 , respectively . the specified items recorded in 2012 unfavorably impacted diluted earnings per share from continuing operations by $ 0.06 per share . financial instrument market risk we selectively use financial instruments to manage market risk , primarily foreign currency exchange risk and interest rate risk relating to our ongoing business operations . the counterparties to these contracts are highly rated financial institutions . we do not enter into financial instruments for trading or speculative purposes . foreign exchange risk bd and its subsidiaries transact business in various foreign currencies throughout europe , asia pacific , canada , japan and latin america . we face foreign currency exposure from the effect of fluctuating exchange rates on payables and receivables relating to transactions that are denominated in currencies other than our functional currency . these payables and receivables primarily arise from intercompany transactions . we hedge substantially all such exposures , primarily through the use of forward contracts . we also face currency exposure that arises from translating the results of our worldwide operations , including sales , to the u.s. dollar at exchange rates that have fluctuated from the beginning of a reporting period . from time to time , we may purchase forward contracts and options to hedge certain forecasted transactions that are denominated in foreign currencies in order to partially protect against a reduction in the value of future earnings resulting from adverse foreign exchange rate movements . gains or losses on derivative instruments are largely offset by the gains or losses on the underlying hedged transactions . we did not enter into contracts to hedge cash flows in fiscal year 2014 or 2013. derivative financial instruments are recorded on our balance sheet at fair value . for foreign currency derivatives , market risk is determined by calculating the impact on fair value of an assumed change in foreign exchange rates relative to the u.s. dollar . fair values were estimated based upon observable inputs , specifically spot currency rates and foreign currency prices for similar assets and liabilities . with respect to the derivative instruments outstanding at september 30 , 2014 and 2013 , the impact changes in the u.s. dollar would have on pre-tax earnings was estimated as follows : replace_table_token_14_th 29 these calculations do not reflect the impact of exchange gains or losses on the underlying transactions that would substantially offset the results

net cash flows from continuing operating activities net cash provided by continuing operating activities was $ 1.75 billion , $ 1.72 billion and $ 1.69 billion in 2014 , 2013 and 2012 , respectively , and was primarily attributable to income from continuing operations , as adjusted for depreciation and amortization . the 2014 change in operating assets and liabilities was a net use of cash and primarily reflected higher levels of inventory and prepaid expenses , partially offset by higher levels of accounts payable and accrued expenses . the 2014 change in operating liabilities included the payment of $ 22 million under a settlement agreement related to indirect purchaser antitrust class action cases . for further discussion regarding this matter , refer to note 5 to the consolidated financial statements contained in item 8. financial statements and supplementary data . the change in accounts receivable includes a $ 36 million payment of government receivables balances in spain . further discussion regarding government receivables is provided in note 13 to the consolidated financial statements contained in item 8. financial statements and supplementary data . net cash provided by continuing operating activities in 2014 was reduced by changes in the pension obligation resulting primarily from discretionary cash contributions of $ 75 million . an additional discretionary contribution of $ 40 million was made to the u.s. pension plan in october 2014. the net change in working capital in 2013 was primarily driven by an increase in accrued payables , reflecting the charge from the rti litigation verdict , partially offset by higher inventory levels and prepaid expenses . net cash provided by continuing operating activities in 2013 was reduced by changes in the pension obligation resulting primarily from discretionary cash contributions of approximately $ 138 million . net cash flows from continuing investing activities capital expenditures our investments in capital expenditures are focused on projects that enhance our cost structure and manufacturing capabilities , and support our strategy of geographic expansion with select investments in growing markets .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```net cash flows from continuing operating activities net cash provided by continuing operating activities was $ 1.75 billion , $ 1.72 billion and $ 1.69 billion in 2014 , 2013 and 2012 , respectively , and was primarily attributable to income from continuing operations , as adjusted for depreciation and amortization . the 2014 change in operating assets and liabilities was a net use of cash and primarily reflected higher levels of inventory and prepaid expenses , partially offset by higher levels of accounts payable and accrued expenses . the 2014 change in operating liabilities included the payment of $ 22 million under a settlement agreement related to indirect purchaser antitrust class action cases . for further discussion regarding this matter , refer to note 5 to the consolidated financial statements contained in item 8. financial statements and supplementary data . the change in accounts receivable includes a $ 36 million payment of government receivables balances in spain . further discussion regarding government receivables is provided in note 13 to the consolidated financial statements contained in item 8. financial statements and supplementary data . net cash provided by continuing operating activities in 2014 was reduced by changes in the pension obligation resulting primarily from discretionary cash contributions of $ 75 million . an additional discretionary contribution of $ 40 million was made to the u.s. pension plan in october 2014. the net change in working capital in 2013 was primarily driven by an increase in accrued payables , reflecting the charge from the rti litigation verdict , partially offset by higher inventory levels and prepaid expenses . net cash provided by continuing operating activities in 2013 was reduced by changes in the pension obligation resulting primarily from discretionary cash contributions of approximately $ 138 million . net cash flows from continuing investing activities capital expenditures our investments in capital expenditures are focused on projects that enhance our cost structure and manufacturing capabilities , and support our strategy of geographic expansion with select investments in growing markets .
```    
 Suspicious Activity Report : we also consider trends related to certain key financial data , including gross profit margin , selling and administrative expense , investment in research and development , return on invested capital , and cash flows . on october 5 , 2014 , we announced a definitive agreement under which bd will acquire 100 % of carefusion corporation ( carefusion ) for $ 58.00 per share in cash and stock , or a total of approximately $ 12.2 billion , to create a global leader in medication management and patient safety solutions . the transaction is expected to close in the first half of calendar year 2015. under the terms of the transaction , carefusion stockholders will receive $ 49.00 in cash , without interest , and 0.0777 of a share of bd for each share of carefusion . using bd 's closing price as of october 3 , 2014 of $ 115.84 would result in a total cost of $ 58.00 per carefusion share . the value of the consideration transferred for accounting purposes will ultimately be based on the closing share price of bd 's stock on the last trading day prior to the closing date of the transaction , and could materially change . carefusion will operate as part of our medical segment . additional discussion regarding this agreement is provided in note 17 to the consolidated financial statements contained in item 8. financial statements and supplementary data . summary of financial results worldwide revenues in 2014 of $ 8.446 billion increased 4.9 % from the prior year , compared with an increase of 4.5 % in 2013. the components of the total worldwide revenue growth in 2014 and 2013 were as follows : replace_table_token_6_th significant drivers of worldwide revenue growth in 2014 included new product sales and sales in emerging markets . strong medical segment revenue growth in 2014 was driven by emerging market and international safety sales , as well as by sales of insulin pen needles . diagnostics revenue growth in 2014 reflected strong sales of safety-engineered products , as well as solid sales of automated diagnostic platforms and automated microbiology systems . diagnostics revenue growth continues to be unfavorably impacted by continued weaker sales of our women 's health and cancer platform . our biosciences segment 's revenue growth in 2014 was driven primarily by double-digit growth of sales in emerging markets and strong clinical reagent sales in all regions . 22 revenues in the united states of $ 3.417 billion in 2014 increased 1.9 % from 2013. international revenues in 2014 grew 7.0 % to $ 5.029 billion , which reflected an estimated unfavorable foreign exchange translation impact of 0.6 % . u.s. revenue growth in 2014 reflected strong medical and biosciences revenue growth , which was partially offset by the ongoing weaker demand in the diagnostics segment 's women 's health and cancer platform . sales of safety-engineered products in the united states were $ 1.2 billion . international revenues for 2014 reflected growth from all segments , including growth attributable to emerging markets , as well as strong sales of safety-engineered products . international safety-engineered products revenues of $ 1.016 billion grew 10.8 % , including an estimated unfavorable impact of foreign currency translation of 1.5 % , reflecting strong performance in western europe and emerging markets . we continue to invest in research and development , geographic expansion , and new product promotions to drive further revenue and profit growth . our ability to sustain our long-term growth will depend on a number of factors , including our ability to expand our core business ( including geographical expansion ) , develop innovative new products , and continue to improve operating efficiency and organizational effectiveness . while the economic environment for the healthcare industry has stabilized , pricing pressures continue for some of our products . healthcare utilization has continued to stabilize in the united states ; however , any destabilization could adversely impact our u.s. businesses . additionally , macroeconomic challenges in europe continue to constrain healthcare utilization , although we currently view the environment as stable . in emerging markets , the company 's growth is dependent on government funding for healthcare systems . in addition to the economic conditions in the united states and elsewhere , numerous other factors can affect our ability to achieve our goals including , without limitation , increased competition and healthcare reform initiatives . for example , the u.s. patient protection affordable care act contains the medical device excise tax that imposed a 2.3 % tax on certain u.s. sales of medical devices . this tax became effective at the beginning of bd 's second quarter of fiscal year 2013. as a result , this tax incrementally increased selling and administrative expense by $ 14 million in 2014 compared with 2013 , and by $ 40 million in 2013 compared with 2012. our financial position remains strong , with cash flows from operating activities totaling $ 1.75 billion in 2014. at september 30 , 2014 , we had $ 2.74 billion in cash and equivalents and short-term investments . also , we continued to return value to our shareholders in the form of share repurchases and dividends . during 2014 , we repurchased $ 400 million of our common stock and paid cash dividends of $ 421 million . no share repurchases are planned in 2015 , as our share repurchase program has been suspended in connection with the announced agreement to acquire carefusion . each reporting period , we face currency exposure that arises from translating the results of our worldwide operations to the u.s. dollar at exchange rates that fluctuate from the beginning of such period . we evaluate our results of operations on both a reported and a foreign currency-neutral basis , which excludes the impact of fluctuations in foreign currency exchange rates . story_separator_special_tag research and development expense in 2014 additionally reflected ongoing investment in new products and platforms within the medical segment . expenses in 2013 reflected increased investment in new products and platforms in all three segments . net interest expense replace_table_token_13_th the decrease in interest expense in 2014 compared with 2013 primarily reflected lower levels of long-term fixed-rate debt and a reduction of interest payments through fixed-to-floating interest rate swap agreements . for further discussion regarding these swap arrangements , refer to note 12 to the consolidated financial statements contained in item 8. financial statements and supplementary data . the increase in interest expense in 2013 compared with 2012 primarily reflected higher average levels of long-term fixed-rate debt . the increase in interest income in 2014 compared with 2013 reflected higher interest rates on investments outside the united states , partially offset by the impact of lower investment gains on assets related to our deferred compensation plan . the decrease in interest income in 2013 compared with 2012 reflected the impact of lower interest rates on investments outside the u.s. and lower investment gains on assets related to our deferred compensation plan . the offsetting movements in the deferred compensation plan liability were recorded in selling and administrative expense . income taxes the effective tax rate in 2014 was 22.1 % as compared with the 2013 rate of 20.2 % . the effective income tax rate in 2013 would have been higher by 430 basis points excluding the impact on bd 's income mix of the 28 previously discussed litigation matters and pension settlement . the effective income tax rate in 2014 reflected our decision to change our position of permanent reinvestment , with respect to the unremitted earnings of brazil and certain other latin american jurisdictions , the impact of which was more than offset by the benefits resulting from discrete one-time items and geographic mix . the effective income tax rate in 2013 also reflected the favorable impact from various tax settlements in multiple jurisdictions and the reinstatement of the u.s. research and development tax credit , partially offset by a lower benefit on foreign earnings . the effective income tax rate of 24.6 % in 2012 , which was reduced by 20 basis points due to the 2012 pension settlement charge , reflected the favorable impact of various tax settlements in multiple jurisdictions . income and diluted earnings per share from continuing operations income from continuing operations and diluted earnings per share from continuing operations in 2014 were $ 1.185 billion and $ 5.99 , respectively . the previously discussed specified items recorded in 2014 decreased diluted earnings per share from continuing operations by $ 0.25. in addition , the medical device excise tax was in effect for an additional quarter in 2014 compared with 2013 , the impact of which was $ 0.05. the current year 's earnings additionally reflected an estimated $ 0.22 unfavorable impact compared with 2013 from foreign currency translation . income from continuing operations and diluted earnings per share from continuing operations in 2013 were $ 929 million and $ 4.67 , respectively . the previously discussed specified items recorded in 2013 decreased diluted earnings per share from continuing operations in 2013 by $ 1.15. earnings in 2013 also reflected an estimated net unfavorable impact compared with 2012 of foreign currency fluctuations of $ 0.06 per share and an unfavorable impact from the medical device excise tax of $ 0.13 per share . income from continuing operations and diluted earnings per share from continuing operations in 2012 were $ 1.1 billion and $ 5.30 , respectively . the specified items recorded in 2012 unfavorably impacted diluted earnings per share from continuing operations by $ 0.06 per share . financial instrument market risk we selectively use financial instruments to manage market risk , primarily foreign currency exchange risk and interest rate risk relating to our ongoing business operations . the counterparties to these contracts are highly rated financial institutions . we do not enter into financial instruments for trading or speculative purposes . foreign exchange risk bd and its subsidiaries transact business in various foreign currencies throughout europe , asia pacific , canada , japan and latin america . we face foreign currency exposure from the effect of fluctuating exchange rates on payables and receivables relating to transactions that are denominated in currencies other than our functional currency . these payables and receivables primarily arise from intercompany transactions . we hedge substantially all such exposures , primarily through the use of forward contracts . we also face currency exposure that arises from translating the results of our worldwide operations , including sales , to the u.s. dollar at exchange rates that have fluctuated from the beginning of a reporting period . from time to time , we may purchase forward contracts and options to hedge certain forecasted transactions that are denominated in foreign currencies in order to partially protect against a reduction in the value of future earnings resulting from adverse foreign exchange rate movements . gains or losses on derivative instruments are largely offset by the gains or losses on the underlying hedged transactions . we did not enter into contracts to hedge cash flows in fiscal year 2014 or 2013. derivative financial instruments are recorded on our balance sheet at fair value . for foreign currency derivatives , market risk is determined by calculating the impact on fair value of an assumed change in foreign exchange rates relative to the u.s. dollar . fair values were estimated based upon observable inputs , specifically spot currency rates and foreign currency prices for similar assets and liabilities . with respect to the derivative instruments outstanding at september 30 , 2014 and 2013 , the impact changes in the u.s. dollar would have on pre-tax earnings was estimated as follows : replace_table_token_14_th 29 these calculations do not reflect the impact of exchange gains or losses on the underlying transactions that would substantially offset the results

